Tiffany A. Traina and Ayca Gucalp, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Kathy Miller, Indiana University Simon Cancer Center, Indianapolis, IN; Denise A. Yardley, Tennessee Oncology, Nashville; Lee S. Schwartzberg, The West Clinic, Memphis, TN; Janice Eakle, Florida Cancer Specialists, Fort Myers, FL; Joyce O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology, Dallas, TX; William Gradishar, Northwestern University Feinberg School of Medicine; Rita Nanda, University of Chicago, Chicago; Joyce Steinberg, Astellas Pharma, Northbrook, IL; Peter Schmid, Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Eric Winer, Dana-Farber Cancer Institute, Boston, MA; Catherine Kelly, All Ireland Collaborative Oncology Research Group, Dublin, Ireland; Ahmad Awada, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium; Laura Garcia-Estevez, Centro Integral Oncologico Clara Campal, Hospital Madrid Norte-Sanchinarro; Javier Cortes, Ramon y Cajal University Hospital, Madrid, and, Vall d'Hebron Institute of Oncology and Baselga Oncological Institute, Barcelona, Spain; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and Hirdesh Uppal, Amy Peterson, and Iulia Cristina Tudor, Medivation, San Francisco, CA.
J Clin Oncol. 2018 Mar 20;36(9):884-890. doi: 10.1200/JCO.2016.71.3495. Epub 2018 Jan 26.
Purpose Studies suggest that a subset of patients with triple-negative breast cancer (TNBC) have tumors that express the androgen receptor (AR) and may benefit from an AR inhibitor. This phase II study evaluated the antitumor activity and safety of enzalutamide in patients with locally advanced or metastatic AR-positive TNBC. Patients and Methods Tumors were tested for AR with an immunohistochemistry assay optimized for breast cancer; nuclear AR staining > 0% was considered positive. Patients received enzalutamide 160 mg once per day until disease progression. The primary end point was clinical benefit rate (CBR) at 16 weeks. Secondary end points included CBR at 24 weeks, progression-free survival, and safety. End points were analyzed in all enrolled patients (the intent-to-treat [ITT] population) and in patients with one or more postbaseline assessment whose tumor expressed ≥ 10% nuclear AR (the evaluable subgroup). Results Of 118 patients enrolled, 78 were evaluable. CBR at 16 weeks was 25% (95% CI, 17% to 33%) in the ITT population and 33% (95% CI, 23% to 45%) in the evaluable subgroup. Median progression-free survival was 2.9 months (95% CI, 1.9 to 3.7 months) in the ITT population and 3.3 months (95% CI, 1.9 to 4.1 months) in the evaluable subgroup. Median overall survival was 12.7 months (95% CI, 8.5 months to not yet reached) in the ITT population and 17.6 months (95% CI, 11.6 months to not yet reached) in the evaluable subgroup. Fatigue was the only treatment-related grade 3 or higher adverse event with an incidence of > 2%. Conclusion Enzalutamide demonstrated clinical activity and was well tolerated in patients with advanced AR-positive TNBC. Adverse events related to enzalutamide were consistent with its known safety profile. This study supports additional development of enzalutamide in advanced TNBC.
研究表明,一部分三阴性乳腺癌(TNBC)患者的肿瘤表达雄激素受体(AR),可能受益于 AR 抑制剂。本 II 期研究评估了恩扎卢胺在局部晚期或转移性 AR 阳性 TNBC 患者中的抗肿瘤活性和安全性。
采用优化用于乳腺癌的免疫组织化学检测法检测肿瘤中的 AR;细胞核 AR 染色>0%被认为是阳性。患者每天接受恩扎卢胺 160mg,直至疾病进展。主要终点为 16 周时的临床获益率(CBR)。次要终点包括 24 周时的 CBR、无进展生存期和安全性。对所有入组患者(意向治疗[ITT]人群)和至少有一次基线后评估且肿瘤表达≥10%细胞核 AR 的患者(可评估亚组)进行了终点分析。
在入组的 118 例患者中,有 78 例患者可评估。ITT 人群中 16 周时的 CBR 为 25%(95%CI,17%至 33%),可评估亚组中为 33%(95%CI,23%至 45%)。ITT 人群中无进展生存期的中位数为 2.9 个月(95%CI,1.9 至 3.7 个月),可评估亚组中为 3.3 个月(95%CI,1.9 至 4.1 个月)。ITT 人群中总生存期的中位数为 12.7 个月(95%CI,8.5 个月至未达到),可评估亚组中为 17.6 个月(95%CI,11.6 个月至未达到)。唯一的治疗相关 3 级或更高级别的不良事件是疲劳,发生率>2%。
恩扎卢胺在晚期 AR 阳性 TNBC 患者中表现出临床活性且耐受性良好。与恩扎卢胺相关的不良事件与其已知的安全性特征一致。本研究支持恩扎卢胺在晚期 TNBC 中的进一步开发。